Skip to main content
SpringerLink
Log in

Die Neuro-Endokrino-Immunologie der Multiplen Sklerose

Wechselwirkungen zwischen Immunsystem, endokrinem System und Nervensystem

  • Originalarbeit
  • Published:
Psychopraxis Aims and scope Submit manuscript

Zusammenfassung

Auf Basis des aktuellen Wissensstandes zu Wechselwirkungen zwischen dem Nervensystem, dem Immunsystem und dem endokrinen System, stellt sich die Frage, welche Bedeutung hormonelle, neurologische und assoziierte psychologische Faktoren für das Ausbrechen und den Verlauf einer Multiplen Sklerose haben. Andererseits gilt es zu bestimmen, welchen Einfluss die Entzündungsaktivität im Rahmen einer Multiplen Sklerose auf das Hormonsystem und das Nervensystem ausübt und ob dadurch bislang schlecht erklärbare, neuropsychologische und neuropsychiatrische Symptome besser verstanden werden können. Diese Übersicht ist eine Analyse möglicher „neuro-endokrino-immunologischer Netzwerke“ und deren Bedeutung für Symptomatik und Verlauf der Multiplen Sklerose.

Summary

Interactions between the nervous system, the immune system and the endocrine system raise our interest in the role of hormonal, neuronal and neuroendocrine factors in the disease process of multiple sclerosis. In this context it is essential to evaluate the non-lesional influences of immunological and inflammatory mechanisms on the nervous system and the endocrine system of patients with multiple sclerosis and to improve the understanding of hitherto elusive, neuropsychiatric and neuropsychological phenomena. This review serves as an analysis of “neuro-endocrino-immunological networks” in multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Noseworthy JH, Lucchinetti C, Rodriguez M and Weinshenker BG (2000). Multiple Sclerosis. N Engl J Med 343: 938–952

    Article  PubMed  CAS  Google Scholar 

  2. Steinman L, Martin R, Bernard C, Conlon P and Oksenberg JR (2002). Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 25: 491–505

    Article  PubMed  CAS  Google Scholar 

  3. Hemmer B, Archelos JJ and Hartung HP (2004). New concepts in the immunopathogenesis of Multiple Sclerosis. Nature Reviews Neuroscience 3: 291–301

    Article  CAS  Google Scholar 

  4. Sospedra M and Martin R (2005). Immunology of multiple sclerosis. Annu Rev Immunol. 23: 683–747

    Article  PubMed  CAS  Google Scholar 

  5. GAMES, Transatlantic Multiple Sclerosis Genetics Cooperative. (2003) A metaanalysis of whole genome linkage screens in multiple sclerosis. J. Neuroimmunol.143: 39–46

    Google Scholar 

  6. Dyment DA, Ebers GC and Sadovnick AD (2004). Genetics of multiple sclerosis. Lancet Neurol 3: 104–110

    Article  PubMed  CAS  Google Scholar 

  7. Siegert RJ and Abernethy DA (2005). Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 76: 469–475

    Article  PubMed  CAS  Google Scholar 

  8. Prosiegel M and Michael C (1993). Neuropsychology and multiple sclerosis: diagnostic and rehabilitative approaches. J Neurol Sci 115(Suppl): S51–S54

    Article  PubMed  Google Scholar 

  9. Benedict RHB, Priore RL, Miller C, Munschauer F and Jacobs L (2001). Personality Disorder in Multiple Sclerosis Correlates With Cognitive Impairment. J Neuropsychiatry Clin Neurosci 13: 70–76

    PubMed  CAS  Google Scholar 

  10. Moller A, Wiedemann G, Rohde U, Backmund H and Sonntag A (1994). Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 89: 117–121

    Article  PubMed  CAS  Google Scholar 

  11. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986). Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348

    PubMed  CAS  Google Scholar 

  12. Kelso A, Groves P, Troutt AB and Francis K (1995). Evidence for the stochastic acquisition of cytokine profile by CD4+ T cells activated in a T helper type 2-like response in vivo. Eur J Immunol 25: 1168

    Article  PubMed  CAS  Google Scholar 

  13. Karulin AY, Hesse MD, Lehmann T, Lehmann M and Paul V (2000). Single-Cytokine-Producing CD4 Memory Cells Predominate in Type 1 and Type 2 Immunity. J Immunol 164: 1862–1872

    PubMed  CAS  Google Scholar 

  14. Greve B, Magnusson CG, Melms A and Weissert R (2001). Immunoglobulin isotypes reveal a predominant role of type 1 immunity in multiple sclerosis. J Neuroimmunol 121: 120–125

    Article  PubMed  CAS  Google Scholar 

  15. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H and Hohlfeld R (1999). Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 189: 865–870

    Article  PubMed  CAS  Google Scholar 

  16. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK and Ting JP (2001). TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4: 1116–1122

    Article  PubMed  CAS  Google Scholar 

  17. Aloisi F, Ria F and Adorini L (2000). Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 21: 141–147

    Article  PubMed  CAS  Google Scholar 

  18. Coo H and Aronson KJ (2004). A systematic review of several potential non-genetic risk factors for multiple sclerosis. Neuroepidemiology 23: 1–12

    Article  PubMed  CAS  Google Scholar 

  19. Wucherpfennig KW and Strominger JL (1995). Molecular mimicry in T-cell mediated autoimmunity: viral peptides activate T cell clones specific for myelin basic protein. Cell 80: 695–705

    Article  PubMed  CAS  Google Scholar 

  20. Konsman JP (2000) Immune-to-brain communication: a functional neuroanatomical analysis. Gröningen University/Bordeaux II University

  21. Mascarucci P, Perego C, Terrazzino S and De Simoni MG (1998). Glutamate release in the nucleus tractus solitarius induced by peripheral lipopolysaccharide and interleukin-1 beta. Neuroscience 86: 1285–1290

    Article  PubMed  CAS  Google Scholar 

  22. Ericsson A, Kovacs KJ and Sawchenko PE (1994). A functional anatomical analysis of central pathways subserving the effects of interleukin- 1 on stress-related neuroendocrine neurons. J Neurosci 14: 897–913

    PubMed  CAS  Google Scholar 

  23. Sawchenko PE and Swanson LW (1982). The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat. Brain Res 257: 275–325

    PubMed  CAS  Google Scholar 

  24. Tkacs NC and Li J (1999). Immune stimulation induces Fos expression in brainstem amygdala afferents. Brain Res Bull 48: 223–231

    Article  PubMed  CAS  Google Scholar 

  25. Whitacre CC (1999). Sex Differences in Autoimmune Disease: Focus on Multiple Sclerosis. Science 283: 1278

    Article  Google Scholar 

  26. Chikanza IC (1999). Prolactin and Neuroimmunomodulation: In Vitro and in Vivo Observations. Ann NY Acad Sci 876: 119–130

    Article  PubMed  CAS  Google Scholar 

  27. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P and Moreau T (1998). The Pregnancy in Multiple Sclerosis Group: Rate of Pregnancy-Related Relapse in Multiple Sclerosis. N Engl J Med 339: 285–291

    Article  PubMed  CAS  Google Scholar 

  28. Wei T and Lightman SL (1997). The neuroendocrine axis in patients with multiple sclerosis. Brain 120: 1067–1076

    Article  PubMed  Google Scholar 

  29. Foster SC, Daniels C, Bourdette DN and Bebo BF (2003). Dysregulation of the hypothalamic-pituitary- gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol 140: 78–87

    Article  PubMed  CAS  Google Scholar 

  30. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, Crane M, Kanik KS and Chrousos GP (2001). IL-12, TNF-alpha, and Hormonal Changes during Late Pregnancy and Early Postpartum: Implications for Autoimmune Disease Activity during These Times. J Clin Endocrinol Metab 86: 4933–4938

    Article  PubMed  CAS  Google Scholar 

  31. Gilmore W, Weiner LP and Correale J (1997). Effect of estradiol on cytokine secretion by proteolipid protein- specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 158: 446–451

    PubMed  CAS  Google Scholar 

  32. Azar ST and Yamout B (1999). Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res 25: 207–214

    Article  PubMed  CAS  Google Scholar 

  33. Kira J, Harada M, Yamaguchi Y, Shida N and Goto I (1991). Hyperprolactinemia in multiple sclerosis. J Neurol Sci 102: 61–66

    Article  PubMed  CAS  Google Scholar 

  34. Michelson D, Stone L, Galliven E, Magiakou MA, Chrousos GP, Sternberg EM and Gold PW (1994). Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J Clin Endocrinol Metab 79: 848–853

    Article  PubMed  CAS  Google Scholar 

  35. Huitinga IE, Erkut ZA, Van Beurden D and Swaab DF (2003). The Hypothalamo-Pituitary- Adrenal Axis in Multiple Sclerosis. Ann NY Acad Sci 992: 118–128

    Article  PubMed  CAS  Google Scholar 

  36. Gironi M, Furlan R, Rovaris M, Comi G, Filippi M and Panerai AE (2003). {beta} endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis. J Neurol Neurosurg Psychiatry 74: 495–497

    Article  PubMed  CAS  Google Scholar 

  37. Sandyk R and Awerbuch GI (1992). Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis. Int J Neurosci 67: 173–186

    Article  PubMed  CAS  Google Scholar 

  38. Lassmann H (1998). Neuropathology in multiple sclerosis: new concepts. Mult Scler 4: 93–98

    PubMed  CAS  Google Scholar 

  39. Garcia-Segura LM, Azcoitia I and DonCarlos LL (2001). Neuroprotection by estradiol. Prog Neurobiol 63: 29–60

    Article  PubMed  CAS  Google Scholar 

  40. Soldan SS, Retuerto AI, Alvarez S, Nancy L and Voskuhl RR (2003). Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol. J Immunol 171: 6267–6274

    PubMed  CAS  Google Scholar 

  41. Dalal M, Kim S and Voskuhl RR (1997). Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen- specific T lymphocyte response. J Immunol 159: 3–6

    PubMed  CAS  Google Scholar 

  42. Piccinni MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L, Sampognaro S, Parronchi P, Manetti R, Annunziato F and Livi C (1995). Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol 155: 128–133

    PubMed  CAS  Google Scholar 

  43. Tomassini V, Onesti E, Mainero C, Giugni E, Paolillo A, Salvetti M, Nicoletti F and Pozzilli C (2005). Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 76: 272–275

    Article  PubMed  CAS  Google Scholar 

  44. Kumpfel T, Then Bergh F, Friess E, Uhr M, Yassouridis A, Trenkwalder C and Holsboer F (1999). Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. Neuroendocrinology 70: 431–438

    Article  PubMed  CAS  Google Scholar 

  45. Du Caigan K, Wahid M and Subramaniam S (2001). Administration of Dehydroepiandrosterone Suppresses Experimental Allergic Encephalomyelitis in SJL/J Mice. J Immunol 167: 7094–7101

    Google Scholar 

  46. Tellez N, Comabella M, Julia E, Rio J, Tintore M, Brieva L, Nos C and Montalban X (2006). Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Mult Scler 12: 487–94

    Article  PubMed  CAS  Google Scholar 

  47. Heesen C, Gold SM, Bruhn M, Monch A and Schulz KH (2002). Prolactin stimulation in multiple sclerosis - an indicator of disease subtypes and activity?. Endocr Res 28: 9–18

    Article  PubMed  CAS  Google Scholar 

  48. Li-Yuan and Yu-Lee (2002). Prolactin Modulation of Immune and Inflammatory Responses. Recent Prog Horm Res 57: 435–455

    Article  Google Scholar 

  49. Neidhart M (1997). Serum levels of interleukin- 1 beta, luteinizing hormone and prolactin correlate with the expression of CD45 isoforms on CD4+ peripheral blood T lymphocytes in healthy women. Ann Hematol 75: 155–9

    Article  PubMed  CAS  Google Scholar 

  50. Knöferl MW, Angele MK, Ayala A, Cioffi WG, Bland KI and Chaudry IH (2000). Insight into the mechanism by which metoclopramide improves immune functions after trauma-hemorrhage. Am J Physiol Cell Physiol 279: C72–C80

    PubMed  Google Scholar 

  51. Dijkstra CD, Van der Voort ER, De Groot CJ, Huitinga I, Uitdehaag BM, Polman CH, and Berkenbosch F (1994). Therapeutic effect of the D2-dopamine agonist bromocriptine on acute and relapsing experimental allergic encephalomyelitis. Psychoneuroendocrinology 19: 135–42

    Article  PubMed  CAS  Google Scholar 

  52. Bissay V, De Klippel N, Herroelen L, Schmedding E, Buisseret T, Ebinger G, and De Keyser J (1994). Bromocriptine therapy in multiple sclerosis: an open label pilot study. Clin Neuropharmacol 17: 473–6

    Article  PubMed  CAS  Google Scholar 

  53. Bergh FT, Kumpfel T, Trenkwalder C, Rupprecht R and Holsboer F (1999). Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology 53: 772–778

    Google Scholar 

  54. Schumann EM, Kumpfel T, Bergh FT, Trenkwalder C, Holsboer F and Auer DP (2002). Activity of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: correlations with gadolinium-enhancing lesions and ventricular volume. Ann Neurol 51: 763–777

    Article  PubMed  Google Scholar 

  55. Turnbull AV and Rivier CL (1999). Regulation of the Hypothalamic-Pituitary-Adrenal Axis by Cytokines: Actions and Mechanisms of Action. Physiol Rev 79: 1–71

    PubMed  CAS  Google Scholar 

  56. Bergh TB, Kümpfel T, Grasser A, Rupprecht R, Holsboer F and Trenkwalder C (2001). Combined Treatment with Corticosteroids and Moclobemide Favors Normalization of Hypothalamo- Pituitary-Adrenal Axis Dysregulation in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double Blind Trial. J Clin Endocrinol Metab 86: 1610–1615

    Article  CAS  Google Scholar 

  57. Chrousos GP (2000). The Stress Response and Immune Function: Clinical Implications: The 1999 Novera H. Spector Lecture. Ann NY Acad Sci 917: 38–67

    Article  CAS  Google Scholar 

  58. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W and Chrousos GP (1999). Tumor Necrosis Factor-alpha decreases, and Interleukin- 10 increases, the Sensitivity of Human Monocytes to Dexamethasone: Potential Regulation of the Glucocorticoid Receptor. J Clin Endocrinol Metab 84: 2834–2839

    Article  PubMed  CAS  Google Scholar 

  59. Van Winsen LM, Muris DF, Polman CH, Dijkstra CD, Van den Berg TK, and Uitdehaag BM(2005). Sensitivity to glucocorticoids is decreased in relapsing remitting multiple sclerosis. J Clin Endocrinol Metab. 90: 734–40

    Article  PubMed  CAS  Google Scholar 

  60. Gironi M, Martinelli V, Brambilla E, Furlan R, Panerai AE and Comi G (2000). beta-Endorphin Concentrations in Peripheral Blood Mononuclear Cells of Patients With Multiple Sclerosis: Effects of Treatment With Interferon Beta. Arch Neurol 57: 1178–1181

    Article  PubMed  CAS  Google Scholar 

  61. Mahajan SD, Schwartz SA, Shanahan TC, Chawda RP and Nair MPN (2002). Morphine Regulates Gene Expression of alpha- and beta-Chemokines and Their Receptors on Astroglial Cells Via the Opioid micro-Receptor. J Immunol 169: 3589–3599

    PubMed  CAS  Google Scholar 

  62. Weber RJ and Pert A (1989). The periaqueductal gray matter mediates opiate-induced immunosuppression. Science 245: 188–190

    Article  PubMed  CAS  Google Scholar 

  63. Bencsics A, Elenkov IJ and Vizi ES (1997). Effect of morphine on lipopolysaccharide-induced tumor necrosis factor-alpha production in vivo: involvement of the sympathetic nervous system. J Neuroimmunol 73: 1–6

    Article  PubMed  CAS  Google Scholar 

  64. Sandyk R and Awerbuch GI (1994). Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis. Int J Neurosci 75: 229–237

    Article  PubMed  CAS  Google Scholar 

  65. Sandyk R and Awerbuch GI (1991). The pineal gland in multiple sclerosis. Int J Neurosci 61: 61–67

    Article  PubMed  CAS  Google Scholar 

  66. Lipton JM and Catania A (1998). Mechanisms of Antiinflammatory Action of the Neuroimmunomodulatory Peptide alpha-MSH. Ann NY Acad Sci 840: 373–380

    Article  PubMed  CAS  Google Scholar 

  67. Morrey KM, McLachlan JA, Serkin CD and Bakouche O (1994). Activation of human monocytes by the pineal hormone melatonin. J Immunol 153: 2671–2680

    PubMed  CAS  Google Scholar 

  68. Maestroni GJ (1999). MLT and the immunehematopoietic system. Adv Exp Med Biol 460: 395–405

    Article  PubMed  CAS  Google Scholar 

  69. Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR and Guerrero JM (1999). Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci 65: 2143–2150

    Article  PubMed  CAS  Google Scholar 

  70. Kuhlwein E and Irwin M (2001). Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J Neuroimmunol 117: 51–57

    Article  PubMed  CAS  Google Scholar 

  71. Kang JC, Ahn M, Kim YS, Moon C, Lee Y and Wie MB (2001). Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2: 85–89

    PubMed  CAS  Google Scholar 

  72. Hansson I, Holmdahl R and Mattsson R (1990). Constant darkness enhances autoimmunity to type II collagen and exaggerates development of collagen-induced arthritis in DBA/1 mice. J Neuroimmunol 27: 79–84

    Article  PubMed  CAS  Google Scholar 

  73. Munger KL, Zhang SM, O‘Reilly E, Olek MJ, Willett WC, Ascherio A, Hernan and MA (2004). Vitamin D intake and incidence of multiple sclerosis. Neurology 62: 60–65

    PubMed  CAS  Google Scholar 

  74. Deluca HF and Cantorna MT (2001). Vitamin D: its role and uses in immunology. FASEB J 15: 2579–2585

    Article  PubMed  CAS  Google Scholar 

  75. Dunn AJ (2001). Effects of cytokines and infections on brain neurochemistry. In: Ader, R, Felten, DL and Cohen, N (eds) Psychoneuroimmunology., pp 649–666. Academic Press, New York

    Google Scholar 

  76. Lachenecker P, Reiners K, Krauser M, Wolf A and Toyka KV (2001). Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 7: 327–334

    Google Scholar 

  77. McDougall AJ and McLeod JG (2003). Autonomic nervous system function in multiple sclerosis. J Neurol Sci 215: 79–85

    Article  PubMed  CAS  Google Scholar 

  78. Gunal DI, Afsar N, Tanridag T and Aktan S (2002). Autonomic dysfunction in multiple sclerosis: correlation with disease-related parameters. Eur Neurol 48: 1–5

    Article  PubMed  Google Scholar 

  79. Flachenecker P, Rufer A, Bihler I, Hippel C, Reiners K and Toyka KV (2003). Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 61: 851–853

    PubMed  CAS  Google Scholar 

  80. Rajda C, Bencsik K, Vecsei L and Bergquist J (2002). Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J Neuroimmunol 124: 93–100

    Article  PubMed  CAS  Google Scholar 

  81. Elenkov IJ, Wilder RL, Chrousos GP and Vizi ES (2000). The Sympathetic Nerve - An Integrative Interface between Two Supersystems: The Brain and the Immune System. Pharmacol Rev 52: 595–638

    PubMed  CAS  Google Scholar 

  82. Tracey KJ (2002). The inflammatory reflex. Nature 420: 853–859

    Article  PubMed  CAS  Google Scholar 

  83. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI and Watkins LR (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458–462

    Article  PubMed  CAS  Google Scholar 

  84. Bernik TR, Friedman SG, Ochani M, Di- Raimo R, Ulloa L, Yang H (2002) Pharmacological Stimulation of the Cholinergic Antiinflammatory Pathway. J Exp Med 195: 781-788

    Google Scholar 

  85. Connor TJ, Song C, Leonard BE, Merali Z and Anisman H (1998). An assessment of the effects of central interleukin-1beta, −2, −6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine, and immune parameters in the rat. Neuroscience 84: 923–933

    Article  PubMed  CAS  Google Scholar 

  86. Arnett PA, Higginson CI and Randolph JJ (2001). Depression in multiple sclerosis: relationship to planning ability. J Int Neuropsychol Soc 7: 665–674

    Article  PubMed  CAS  Google Scholar 

  87. Rao SM, Leo GJ, Bernardin L and Unverzagt F (1991). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41: 685–691

    PubMed  CAS  Google Scholar 

  88. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borras C, Auriacombe S, Brochet B, Falautano M, Filippi M, Herisse-Dulo L, Montalban X, Parrcira E, Polman CH, De Sa J and Langdon DW (1999). Cognitive function in primary progressive and transitional progressive multiple sclerosis: A controlled study with MRI correlates. Brain 122: 1341–1348

    Article  PubMed  Google Scholar 

  89. Demaree HA, DeLuca J, Gaudino EA and Diamond Bruce J (1999). Speed of information processing as a key deficit in multiple sclerosis: implications for rehabilitation. J Neurol Neurosurg Psychiatry 67: 661–663

    Article  PubMed  CAS  Google Scholar 

  90. Arnett PA, Rao SM, Grafman J, Bernardin L, Luchetta T, Binder JR and Lobeck L (1997). Executive functions in multiple sclerosis: an analysis of temporal ordering, semantic encoding, and planning abilities. Neuropsychology 11: 535–544

    Article  PubMed  CAS  Google Scholar 

  91. Plata-Salaman CR (1998). Cytokine-Induced Anorexia: Behavioral, Cellular and Molecular Mechanisms. Ann NY Acad Sci 856: 160–170

    Article  PubMed  CAS  Google Scholar 

  92. Anisman H and Merali Z (1999). Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461: 199–233

    Article  PubMed  CAS  Google Scholar 

  93. McEwen BS and Alves SE (1999). Estrogen Actions in the Central Nervous System. Endocr Rev 20: 279–307

    Article  PubMed  CAS  Google Scholar 

  94. Sherwin BB (2003). Estrogen and cognitive functioning in women. Endocr Rev 24: 133–151

    Article  PubMed  CAS  Google Scholar 

  95. Klaiber EL, Broverman DM, Vogel W, Peterson LG and Snyder MB (1996). Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroendocrinology 21: 575–592

    Article  PubMed  CAS  Google Scholar 

  96. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C and Lu ZN (1998). Ovarian steroids and serotonin neural function. Mol Neurobiol 18: 87–123

    Article  PubMed  CAS  Google Scholar 

  97. Seidman SN and Walsh BT (1999). Testosterone and depression in aging men. Am J Geriatr Psychiatry 7: 18–33

    PubMed  CAS  Google Scholar 

  98. Sandyk R and Awerbuch GI (1994). The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link. Int J Neurosci 76: 249–257

    Article  PubMed  CAS  Google Scholar 

  99. Sandyk R and Awerbuch GI (1996). Suicidal behavior is attenuated in patients with multiple sclerosis by treatment with electromagnetic fields. Int J Neurosci 87: 5–15

    Article  PubMed  CAS  Google Scholar 

  100. Checkley S (1996). The neuroendocrinology of depression and chronic stress. Br Med Bull 52: 597–617

    PubMed  CAS  Google Scholar 

  101. Owens MJ and Nemeroff CB (1991). Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43: 425–473

    PubMed  CAS  Google Scholar 

  102. De Souza EP (1990). Role of corticotropinreleasing factor in neuropsychiatric disorders and neurodegenerative diseases. In: Seamon, KB (eds) Annual reports in medicinal chemistry., pp 215–224. Academic Press, San Diego

    Google Scholar 

  103. Kordon C, Drouva SV, Martinez de la Escalera G and Weiner RI (1994). Role of classic and peptide neuromediators in the neuronedocrine regulation of luteinizing hormone and prolactin. In: Knobil, E and Neill, JD (eds) The Physiology of Reproduction, pp 1621–1681. Raven Press, New York

    Google Scholar 

  104. Landfield PW (1987). Modulation of brain aging correlates by long-term alterations of adrenal steroids and neurally-active peptides. Prog Brain Res 72: 279–300

    Article  PubMed  CAS  Google Scholar 

  105. Luine VN, Spencer RL and McEwen BS (1993). Effects of chronic corticosterone ingestion on spatial memory performance and hippocampal serotonergic function. Brain Res 616: 65–70

    Article  PubMed  CAS  Google Scholar 

  106. Landfield PW and Eldridge JC (1994). The glucocorticoid hypothesis of age-related hippocampal neurodegeneration: role of dysregulated intraneuronal calcium. Ann NY Acad Sci 746: 308–321

    Article  PubMed  CAS  Google Scholar 

  107. Ronaldde Kloet E, Vreugdenhil E, Oitzl MS and Joëls M (1998). Brain Corticosteroid Receptor Balance in Health and Disease. Endocrine Reviews 19: 269–301

    Article  Google Scholar 

  108. Ader R and Cohen N (1993). Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol 44: 53–85

    Article  PubMed  CAS  Google Scholar 

  109. Roszman TL, Cross RJ, Brooks WH and Markesbery WR (1985). Neuroimmunomodulation: effects of neural lesions on cellular immunity. In: Gulliemin, R, Cohn, M, and Melnechuk, T (eds) Neural modulation of immunity, pp 95–109. Raven Press, New York

    Google Scholar 

  110. Mohr DC, Goodkin DE, Bacchetti P, Boudewyn AC, Huang L, Marrietta P, Cheuk W and Dee B (2000). Psychological stress and the subsequent appearance of new brain MRI lesions in MS. Neurology 55: 55–61

    PubMed  CAS  Google Scholar 

  111. Buljevac D, Hop WCJ, Reedeker W, Janssens ACJW, van der Meche FGA, van Doorn PA, and Hintzen RQ (2003). Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ 327: 646–650

    Article  PubMed  CAS  Google Scholar 

  112. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA and Wolinsky JS (1999). The relationship of MS to physical trauma and psychological stress: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 52: 1737–1750

    PubMed  CAS  Google Scholar 

  113. Nisipeanu P and Korczyn AD (1993). Psychological stress as risk factor for exacerbations in multiple sclerosis. Neurology 43: 1311–1312

    PubMed  CAS  Google Scholar 

  114. Panitch HS, Hirsch RL, Haley AS and Johnson KP (1987). Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1: 893–895

    Article  PubMed  CAS  Google Scholar 

  115. Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E and Carton H (1988). Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 140: 1506–1510

    PubMed  CAS  Google Scholar 

  116. Bartsch H and Bartsch C (1981). Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm 52: 269–279

    Article  PubMed  CAS  Google Scholar 

  117. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS and Williams GT (1994). Transdermal Nicotine for Active Ulcerative Colitis. N Engl J Med 330: 811–815

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Abteilung, Krankenhaus Hietzing, Wolkersbergenstr. 1, 1130, Wien, Austria

    Robert Paur & M. Schmidbauer

Authors
  1. Robert Paur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Schmidbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Paur.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paur, R., Schmidbauer, M. Die Neuro-Endokrino-Immunologie der Multiplen Sklerose. Psychopraxis 12, 18–28 (2009). https://doi.org/10.1007/s00739-009-0153-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00739-009-0153-4

Search

Navigation